For decades, millions of people lived in a private, exhausting loop of rituals—checking a door lock ten times, scrubbing hands until they bled, or arranging objects in a precise, agonizing order—believing they were alone in their “craziness.” The shame was often as debilitating as the symptoms themselves. That silence began to break with the work of Dr. Judith Rapoport, a pioneering child psychiatrist whose research and writing transformed obsessive-compulsive disorder (OCD) from a misunderstood quirk of “strict parenting” into a recognized neurological condition.
The Judith Rapoport obituary marks the passing of a woman who did more than publish papers; she provided a vocabulary for the “tortured souls” she treated. By blending rigorous clinical research with a rare ability to communicate with the public, Rapoport dismantled the stigma surrounding OCD and helped steer the field of child psychiatry toward an evidence-based, biological framework.
Rapoport died on March 7, 2026, at the age of 92. Her legacy is defined by a refusal to accept the medical orthodoxy of her time, whether that meant challenging the gender barriers of Harvard Medical School or rejecting the prevailing Freudian theories that blamed mental illness on unconscious conflict and childhood trauma.
Dismantling the Stigma of OCD
Before the late 1980s, OCD was frequently viewed through a psychodynamic lens. It was often attributed to overly rigid upbringings or strict potty training. Rapoport challenged this narrative, demonstrating that OCD was effectively a neurological disease that often ran in families and affected as many as 2% of the population.
Her most significant contribution to public health came in 1989 with the publication of The Boy Who Couldn’t Stop Washing. Written in a jargon-free style, the book was translated into more than 20 languages and served as a lifeline for patients who had previously hidden their rituals from family and friends. For many, the book was the first time they realized their experience was a medical condition rather than a personal failing.
Rapoport’s impact was not limited to the page. She conducted a pivotal double-blind drug trial in 1989 using the antidepressant clomipramine. This research provided the critical evidence necessary for the U.S. Food and Drug Administration (FDA) to approve the medication for the treatment of OCD, offering a pharmacological path to relief for those who had previously found no solace in traditional talk therapy.
“I thought I was the only person touching things, lining them up, tens, maybe hundreds of times a day,” said Charles Gentz, who has OCD. “It was mental torment. I thought I was crazy. And then I read Judy Rapoport’s book and the shame was washed away.”
A Career of Firsts and Friction
Rapoport’s path to the top of the medical establishment was rarely smooth. After graduating magna cum laude from Swarthmore College in 1955, she entered Harvard Medical School, where she was one of only five women in her class. She frequently faced resentment from male peers who believed her presence occupied a seat better suited for a man.
Despite this friction, she excelled, graduating as a medical doctor in 1959. Her early career was marked by a global curiosity and a commitment to marginalized populations. In 1962, she and her husband, Stanley Rapoport, won fellowships to study in Sweden. While working at the Karolinska Institute in Stockholm, she led critical research into the experiences of American women traveling abroad to seek abortions—a dangerous and clandestine journey for many at the time.
Upon returning to the U.S., Rapoport joined the National Institute of Mental Health (NIMH) in 1976. By 1984, she was appointed head of the NIMH’s newly established child psychiatry branch. In this role, she became a vanguard for the shift toward biological psychiatry, prioritizing brain chemistry and neurology over the “unconscious conflict” models of the past.
Expanding the Boundaries of Child Psychiatry
While OCD was her most public victory, Rapoport’s influence extended to other complex childhood disorders. She applied the same evidence-based rigor to attention deficit hyperactivity disorder (ADHD) and childhood schizophrenia, consistently challenging the prevailing medical wisdom.
In 1978, she published a landmark paper regarding stimulants and hyperactivity. Her research showed that both hyperactive boys and those in a control group responded similarly to amphetamines, with concentration levels improving across the board. This contradicted the belief that stimulants only “calmed” hyperactive children, suggesting a more universal neurological response.
Her work on childhood schizophrenia was equally transformative. Using magnetic resonance imaging (MRI) scans, Rapoport demonstrated that the condition was progressive and associated with a physical loss of brain matter. This provided empirical evidence that schizophrenia was a biological process rather than a result of poor parenting.
| Year | Achievement / Milestone | Impact |
|---|---|---|
| 1959 | Graduated Harvard Medical School | One of the first women to break into the cohort |
| 1978 | Published ADHD amphetamine study | Challenged beliefs on stimulant-specific responses |
| 1984 | Head of NIMH Child Psychiatry Branch | Led the shift toward biological child psychiatry |
| 1989 | Published The Boy Who Couldn’t Stop Washing | Mainstreamed OCD awareness; led to FDA drug approval |
The Ethical Complexity of Research
Rapoport’s commitment to science sometimes blurred the lines between her professional and personal life. In her studies on childhood schizophrenia, she included her own sons, Erik and Stuart, as subjects in the control group. In later years, this decision drew criticism from some quarters of the medical community, who questioned the ethics of using one’s own children in drug trials.
Despite these controversies, her peers recognized her as a pioneer. Gabrielle Shapiro, a professor of clinical psychiatry at the Icahn School of Medicine in New York, noted that Rapoport turned child psychiatry into a “modern, evidence-based discipline.” By the time she retired in 2017, Rapoport had published over 300 scientific papers and earned fellowships in both the U.S. Institute of Medicine and the American Academy of Arts and Sciences.
Outside the clinic and the laboratory, Rapoport was a woman of diverse passions. She was an avid guitar player, a choir singer, and a lover of the theatre, hiking, and gardening. She is survived by her husband, her sons, and four grandsons.
Note: This article provides information regarding psychiatric history and medical research for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
The medical community continues to build upon Rapoport’s foundation, with current research shifting toward targeted neuromodulation and genetic markers for OCD. The next major milestone in this field is expected as new longitudinal studies on early-intervention biological therapies are released in upcoming clinical journals.
We invite readers to share their reflections on Dr. Rapoport’s work or their own experiences with the evolution of mental health care in the comments below.
Keep reading
